On January 5, 2022, amendments came into force amending the Food and Drug Regulations to allow practitioners to request access to restricted drugs through the Special Access Program (SAP), which was previously prohibited. Restricted drugs are controlled substances that are listed in the Schedule to Part J of the Food and Drug Regulations which includes, for example, certain amphetamines and lysergic acid diethylamide (LSD). Health Canada revised its Special Access Program for drugs: Guidance document for industry and practitioners to reflect these amendments. The Guidance also addresses the need for an exemption under the Controlled Drugs and Substances Act, if a restricted drug is authorized for sale through the SAP.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Health Canada’s proposed regulatory amendments to address health product shortages
On June 25, 2024, Health Canada published a notice of intent and Building resilience: Health Canada’s plan to address health product shortages, 2024 to 2028, relating to Health Canada’s plan over the ...Read More -
CIPO expected to resume patent granting on August 20
According to CIPO’s updated roadmap, patent granting should resume on August 20, 2024.Read More -
Release of Statistical Report 2023/2024 for PMNOC Regulations, data protection and CSPs
On August 12, 2024, the Office of Patented Medicines and Liaison of Health Canada released its Statistical Report 2023/2024 for the Patented Medicines (Notice of Compliance) Regulations, Data Protecti...Read More